

**Caution: For Laboratory Use. A research product for research purposes only**

## **Human IL-3 AlphaLISA Detection Kit**

**Product number: AL3134HV/C/F**

### **Contents**

|   |    |
|---|----|
| Product Information .....                 | 2  |
| Quality Control.....                      | 3  |
| Analyte of Interest .....                 | 3  |
| Description of the AlphaLISA Assay .....  | 3  |
| Precautions .....                         | 3  |
| Kit Content: Reagents and Materials ..... | 4  |
| Recommendations .....                     | 5  |
| Assay Procedure .....                     | 5  |
| Data Analysis .....                       | 7  |
| Assay Performance Characteristics .....   | 9  |
| Cell lysate Experiments.....              | 11 |
| Troubleshooting Guide .....               | 14 |

## Product Information

**Application:** This kit is designed for the quantitative determination of human human IL-3 in culture medias, cell lysates, cell supernatents and serum samples using a homogeneous AlphaLISA assay (no wash steps). The kit is using glycosylated human IL-3 as an analyte.

Specifications described below are based on assay performed in AlphaLISA Immunoassay Buffer 1X.

**Sensitivity:** Lower Detection Limit (LDL): 4.6 pg/mL  
Lower Limit of Quantification (LLOQ): 15.9 pg/mL  
EC<sub>50</sub>: 76 ng/mL

**Dynamic range:** 4.6 – 300 000 pg/mL




Figure 1. Typical sensitivity curve in AlphaLISA Immunoassay Buffer. The data was generated using a white Optiplate™-384 microplate and the EnVision® Multilabel Plate Reader 2102 with Alpha option.

**Storage:** Store kit in the dark at +4 °C.

**Stability:** This kit is stable for at least 6 months from the manufacturing date when stored in its original packaging and the recommended storage conditions.

## Quality Control

Lot to lot consistency is confirmed in an AlphaLISA assay. Maximum and minimum signals,  $EC_{50}$  and LDL were measured on the EnVision Multilabel Plate Reader with Alpha option using the protocol described in this technical data sheet. We certify that these results meet our quality release criteria. Maximum counts may vary between bead lots and the instrument used, with no impact on LDL measurement.

## Analyte of Interest

Human IL-3 is a 152 amino acid protein with significant glycosylation in vivo. It is secreted by activated T-cells after response to infection or inflammation and act as a growth factor for T-cells and members of the myeloid cell lineage. It is also a key mediator for survival of hematopoietic cell progenitor stem cells. It acts by binding to a high affinity receptor, IL3R.

The human IL-3 AlphaLISA detection kit allows for the detection of human IL-3 in cell lysates and supernatants, along with serum and plasma. The kit as designed recognizes the glycosylated form of IL-3

## Description of the AlphaLISA Assay

AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm (Figure 2).




Figure 2. AlphaLISA Assay Principle.

## Precautions

- The Alpha Donor beads are light-sensitive. All the other assay reagents can be used under normal light conditions. All Alpha assays using the Donor beads should be performed under subdued laboratory lighting (< 100 lux). Green filters (LEE 090 filters (preferred) or Roscolux filters #389 from Rosco) can be applied to light fixtures.
- Take precautionary measures to avoid contamination of the reagent solutions.

- The Biotinylated Anti-Analyte Antibody contains sodium azide. Contact with skin or inhalation should be avoided.

## Kit Content: Reagents and Materials

| Kit components   | AL3134HV<br>(100 assay points)**                    | AL3134C<br>(500 assay points)                        | AL3134F<br>(5000 assay points)                         |
|--|---|--|--|
| AlphaLISA Anti-IL-3 Acceptor beads stored in PBS, 0.05% Kathon CG/ICP, pH 7.2                        | 20 µL @ 5 mg/mL<br>(1 brown tube, <u>white</u> cap) | 50 µL @ 5 mg/mL<br>(1 brown tube, <u>white</u> cap)  | 500 µL @ 5 mg/mL<br>(1 brown tube, <u>white</u> cap)   |
| Streptavidin (SA)-coated Donor beads stored in 25 mM HEPES, 100 mM NaCl, 0.05% Kathon CG/ICP, pH 7.4 | 40 µL @ 5 mg/mL<br>(1 brown tube, <u>black</u> cap) | 100 µL @ 5 mg/mL<br>(1 brown tube, <u>black</u> cap) | 1 000 µL @ 5 mg/mL<br>(1 brown tube, <u>black</u> cap) |
| Biotinylated Anti-IL-3 Antibody stored in PBS, 0.1% Tween-20, 0.05% NaN <sub>3</sub> , pH 7.4        | 20 µL @ 500 nM<br>(1 tube, <u>black</u> cap)        | 50 µL @ 500 nM<br>(1 tube, <u>black</u> cap)         | 500 µL @ 500 nM<br>(1 tube, <u>black</u> cap)          |
| Lyophilized Glycosylated IL-3 from HEK293 cells ***  | 1 µg<br>(1 tube, <u>clear</u> cap)                  | 1 µg<br>(1 tube, <u>clear</u> cap)                   | 1 µg<br>(1 tube, <u>clear</u> cap)                     |
| AlphaLISA Immunoassay Buffer (10X) *   | 2 mL, 1 small bottle                                | 10 mL, 1 medium bottle                               | 100 mL, 1 large bottle                                 |

\* Extra buffer can be ordered separately (cat # AL000C: 10 mL, cat # AL000F: 100 mL).

\*\* The number of assay points is based on an assay volume of 100 µL in 96-well plates or 50 µL in 96- or 384-well assay plates using the kit components at the recommended concentrations.

\*\*\* Reconstitute lyophilized analyte in 100 µL Milli-Q® grade H<sub>2</sub>O. The reconstituted analyte should be used within 60 minutes or aliquoted into screw-capped 0.5 mL polypropylene vials and stored at -20 °C for future experiments. The aliquoted analyte stored at -20 °C is stable up to 30 days. The reconstituted material can tolerate up to two freeze-thaw cycles. However, freeze-thaw cycles should be avoided if possible. One vial contains an amount of analyte sufficient for performing 10 standard curves. Additional vials can be ordered separately (cat # AL3134S).

Sodium azide should **not** be added to the stock reagents. High concentrations of sodium azide (> 0.001 % final in the assay) might decrease the AlphaLISA signal. Note that sodium azide from the Biotinylated Antibody stock solution will not interfere with the AlphaLISA signal (0.0001% final in the assay).

### Specific additional required reagents and materials:

The following materials are recommended:

| Item                                  | Suggested source | Catalog # |
|---------------------------------------|------------------|-----------|
| TopSeal™-A Plus Adhesive Sealing Film | PerkinElmer Inc. | 6050185   |
| EnVision®-Alpha Reader                | PerkinElmer Inc. | -         |

## Recommendations

- The volume indicated on each tube is guaranteed for single pipetting. Multiple pipetting of the reagents may reduce the theoretical amount left in the tube. To minimize loss when pipetting beads, it is preferable not to pre-wet the tip.
- Centrifuge all tubes (including lyophilized analyte) before use to improve recovery of content (2000g, 10-15 sec). Re-suspend all reagents by vortexing before use.
- Use Milli-Q® grade H<sub>2</sub>O (18 MΩ•cm) to dilute 10X AlphaLISA Immunoassay Buffer.
- When diluting the standard or samples, change tips between each standard or sample dilution. When loading reagents in the assay microplate, change tips between each standard or sample addition and after each set of reagents.
- When reagents are added to the microplate, make sure the liquids are at the bottom of the well.
- Small volumes may be prone to evaporation. It is recommended to cover microplates with TopSeal-A Plus Adhesive Sealing Films to reduce evaporation during incubation. Microplates can be read with the TopSeal-A Plus Film.
- The AlphaLISA signal is detected with an EnVision Multilabel Reader equipped with the Alpha option using the AlphaScreen standard settings (e.g. Total Measurement Time: 550 ms, Laser 680 nm Excitation Time: 180 ms, Mirror: D640as, Emission Filter: M570w, Center Wavelength 570 nm, Bandwidth 100 nm, Transmittance 75%).
- AlphaLISA signal will vary with temperature and incubation time. For consistent results, identical incubation times and temperature should be used for each plate.
- The standard curves shown in this technical data sheet are provided for information only. A standard curve must be generated for each experiment.

## Assay Procedure

IMPORTANT: PLEASE READ THE RECOMMENDATIONS BELOW BEFORE USE

- The protocol described below is an example for generating one standard curve in a 50 µL final assay volume (48 wells, triplicate determinations). The protocols also include testing samples in 452 wells. If a different amount of samples are tested, the volumes of all reagents have to be adjusted accordingly, as shown in the table below. These calculations do not include excess reagent to account for losses during transfer of solutions or dead volumes.
- The standard dilution protocol is provided for information only. As needed, the number of replicates or the range of concentrations covered can be modified.
- Use of four background points in triplicate (12 wells) is recommended when LDL/LLOQ is calculated. One background point in triplicate (3 wells) can be used when LDL/LLOQ is not calculated.

| Format    | # of data points | Final  | Volume |  |                | Plate recommendation  |
|-----------|------------------|--------|--------|--|----------------|---|
|           |                  |        | Sample | AlphaLISA Acceptor beads and Biotinylated Antibody | SA-Donor beads |   |
| AL3134 HV | 100              | 100 µL | 10 µL  | 10 µL  | 80 µL          | White OptiPlate-96 (cat # 6005290)<br>White ½ AreaPlate-96 (cat # 6005560)  |
| AL3134C   | 250              | 100 µL | 10 µL  | 10 µL  | 80 µL          | White OptiPlate-96 (cat # 6005290)<br>White ½ AreaPlate-96 (cat # 6005560)  |
|           | 500              | 50 µL  | 5 µL   | 5 µL   | 40 µL          | White ½ AreaPlate-96 (cat # 6005560)<br>White OptiPlate-384 (cat # 6007290)<br>Light gray AlphaPlate™-384 (cat # 6005350) |
|           | 1 250            | 20 µL  | 2 µL   | 2 µL   | 16 µL          | Light gray AlphaPlate-384 (cat # 6005350)<br>ProxiPlate™-384 Plus (cat # 6008280)<br>White OptiPlate-384 (cat # 6007290)  |
|           | 2 500            | 10 µL  | 1 µL   | 1 µL   | 8 µL           | Light gray AlphaPlate-1536 (cat # 6004350)  |
| AL3134F   | 5 000            | 50 µL  | 5 µL   | 5 µL   | 40 µL          | White ½ AreaPlate-96 (cat # 6005560)<br>White OptiPlate-384 (cat # 6007290)<br>Light gray AlphaPlate-384 (cat # 6005350)  |
|           | 12 500           | 20 µL  | 2 µL   | 2 µL   | 16µL           | Light gray AlphaPlate-384 (cat # 6005350)<br>ProxiPlate-384 Plus (cat # 6008280)<br>White OptiPlate-384 (cat # 6007290)   |
|           | 25 000           | 10 µL  | 1 µL   | 1 µL   | 8 µL           | Light gray AlphaPlate-1536 (cat # 6004350)  |

**2 Step Protocol described below is for 500 assay points including one standard curve (48 wells) and samples (452 wells). If a different amount of samples are tested, the volumes of all reagents have to be adjusted accordingly.**

1) Preparation of 1X AlphaLISA Immunoassay Buffer:

- a. Add 5 mL of 10X AlphaLISA Immunoassay Buffer to 45 mL Milli-Q grade water.

2) Preparation of 1X AlphaLISA Lysis Buffer:

- a. Add 1 mL of 5X AlphaLISA Lysis Buffer to 5 mL of Milli-Q grade water.

3) Preparation human IL-3 analyte standard dilutions:

- a. Reconstitute analyte by adding 100  $\mu$ L of Milli-Q grade water to one tube of analyte to generate a 10  $\mu$ g/mL solution.  
 b. Prepare standard dilutions as follows in 1X AlphaLISA Immunoassay Buffer

| Tube              | Vol. of human IL-3 ( $\mu$ L)  | Vol. of diluent ( $\mu$ L) * | [human IL-3] in standard curve |                      |
|-------------------|--------------------------------|------------------------------|--------------------------------|----------------------|
|                   |                                |                              | (g/mL in 5 $\mu$ L)            | (pg/mL in 5 $\mu$ L) |
| A                 | 10 $\mu$ L of human IL-3 stock | 90                           | 1.00E-06                       | 1 000 000            |
| B                 | 60 $\mu$ L of tube A           | 140                          | 3.00E-07                       | 300 000              |
| C                 | 60 $\mu$ L of tube B           | 120                          | 1.00E-07                       | 100 000              |
| D                 | 60 $\mu$ L of tube C           | 140                          | 3.00E-08                       | 30 000               |
| E                 | 60 $\mu$ L of tube D           | 120                          | 1.00E-08                       | 10 000               |
| F                 | 60 $\mu$ L of tube E           | 140                          | 3.00E-09                       | 3 000                |
| G                 | 60 $\mu$ L of tube F           | 120                          | 1.00E-09                       | 1 000                |
| H                 | 60 $\mu$ L of tube G           | 140                          | 3.00E-10                       | 300                  |
| I                 | 60 $\mu$ L of tube H           | 120                          | 1.00E-10                       | 100                  |
| J                 | 60 $\mu$ L of tube I           | 140                          | 3.00E-11                       | 30                   |
| K                 | 60 $\mu$ L of tube J           | 120                          | 1.00E-11                       | 10                   |
| L                 | 60 $\mu$ L of tube K           | 140                          | 3.00E-12                       | 3                    |
| M ** (background) | 0                              | 100                          | 0                              | 0                    |
| N ** (background) | 0                              | 100                          | 0                              | 0                    |
| O ** (background) | 0                              | 100                          | 0                              | 0                    |
| P ** (background) | 0                              | 100                          | 0                              | 0                    |

\* Dilute standards in diluent (e.g. 1X AlphaLISA Immunoassay Buffer).  
 At low concentrations of analyte, a significant amount of analyte can bind to the vial. Therefore, load the analyte standard dilutions in the assay microplate within 60 minutes of preparation.

\*\* Four background points in triplicate (12 wells) are used when LDL is calculated. If LDL does not need to be calculated, one background point in triplicate can be used (3 wells).

4) Preparation of 10X MIX AlphaLISA Anti-IL-3 Antibody Acceptor beads (100  $\mu$ g/mL) + Biotinylated Anti-IL-3 Antibody (10 nM):


- a. Prepare just before use.  
 b. Add 5  $\mu$ L of 5 mg/mL AlphaLISA Anti-IL-3 Antibody Acceptor Bead and 5  $\mu$ L of 500 nM Biotinylated Anti-IL-3 Antibody to 240  $\mu$ L of 1X AlphaLISA Immunoassay Buffer.

5) Preparation of 1.25X Streptavidin (SA) Donor beads (25  $\mu$ g/mL):

- a. Prepare just before use.  
 b. Keep the beads under subdued laboratory lighting.  
 c. Add 10  $\mu$ L of 5 mg/mL SA-Donor beads to 1990  $\mu$ L of 1X AlphaLISA Immunoassay Buffer.

d.

6) In a white Optiplate (384 wells):



## Data Analysis

- Calculate the average count value for the background wells.
- Generate a standard curve by plotting the AlphaLISA counts versus the concentration of analyte. A log scale can be used for either or both axes. No additional data transformation is required.
- Analyze data according to a nonlinear regression using the 4-parameter logistic equation (sigmoidal dose-response curve with variable slope) and a  $1/Y^2$  data weighting (the values at maximal concentrations of analyte after the hook point should be removed for correct analysis).
- The LDL is calculated by interpolating the average background counts (12 wells without analyte) + 3 x standard deviation value (average background counts + (3xSD)) on the standard curve.
- The LLOQ as measured here is calculated by interpolating the average background counts (12 wells without analyte) + 10 x standard deviation value (average background counts + (10xSD)) on the standard curve. Alternatively, the true LLOQ can be determined by spiking known concentrations of analyte in the matrix and measuring the percent recovery, and then determining the minimal amount of spiked analyte that can be quantified within a given limit (usually +/- 20% or 30% of the real concentration).
- Read from the standard curve the concentration of analyte contained in the samples.
- If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.



## Assay Performance Characteristics

AlphaLISA assay performance described below was determined using the 2 step protocol using AlphaLISA Immunoassay Buffer (IAB).

- Assay Sensitivity:

The LDL was calculated as described above. The values correspond to the lowest concentration of analyte that can be detected in a volume of 5  $\mu$ L using the recommended assay conditions.

| LDL (pg/mL) | Buffer *  | # of experiments |
|-------------|---|------------------|
| 4.6         | IAB   | 7                |
| 1.8         | AlphaLISA Lysis Buffer (ALB)                        | 7                |
| 10.8        | DMEM + 10% FBS                                      | 7                |
| 29.4        | RPMI + 10% FBS                                      | 7                |
| 11.6        | FBS   | 7                |
| 1.7         | RPMI + 10% FBS: AlphaLISA Lysis Buffer 1:1 dilution | 7                |

\* The standard was prepared in these diluents and all other components were diluted in IAB. Note that LDL can be decreased (i.e. sensitivity increased) by increasing the volume of analyte in the assay (e.g. use 10  $\mu$ L of analyte in a final assay volume of 50  $\mu$ L).

Performing assays in RPMI 1640 will see interference from the media. However, diluting samples in RPMI 1:1 with lysis buffer does restore the sensitivity of the kit.

- Assay Precision:

The following assay precision data were calculated from the three independent assays using two different kit lots. In each lot, the analytes were prepared in IAB, AlphaLISA Lysis Buffer, DMEM, RPMI or RPMI: AlphaLISA Lysis Buffer 1:1. Cell culture media was supplemented with 10% FBS. All other components were prepared in IAB. Each assay consisted of one standard curve comprising 12 data points (each in triplicate) and 12 background wells (no analytes). The assays were performed in 384-well format.

- Intra-assay precision:

The intra-assay precision was determined by averaging 6 experiments each with 12 independent determinations in triplicate. Shown as CV%.

| human IL-3 | IAB | Lysis Buffer | DMEM + 10% FBS | RPMI + 10% FBS | FBS | RPMI:Lysis Buffer 1:1 |
|------------|-----|--------------|----------------|----------------|-----|-----------------------|
| CV (%)     | 4.2 | 1.9          | 2.2            | 2.8            | 1.9 | 5.9                   |

- Inter-assay precision:

The inter-assay precision was determined comparing 6 experiments each with 12 independent determinations in triplicate. Shown as CV%.

| human IL-3 | IAB | Lysis Buffer | DMEM + 10% FBS | RPMI + 10% FBS | FBS | RPMI:Lysis Buffer 1:1 |
|------------|-----|--------------|----------------|----------------|-----|-----------------------|
| CV (%)     | 3.7 | 9.4          | 10             | 10             | 9.2 | 9.4                   |

- Spike Recovery:

Known concentrations of analyte were spiked into IAB, DMEM + 10% FBS, RPMI +10% FBS, 100% FBS or RPMI + 10% FBS: Lysis buffer 1:1. All samples, including non-spiked buffer were measured in the assay. Note that the standard curves were prepared in the matrices used for the samples. All other components were diluted in IAB.

| Spiked human IL-3 (ng/mL) | % Recovery |              |                |                |     |                       |
|---------------------------|------------|--------------|----------------|----------------|-----|-----------------------|
|                           | IAB        | Lysis Buffer | DMEM + 10% FBS | RPMI + 10% FBS | FBS | RPMI:Lysis Buffer 1:1 |
| 10                        | 110        | 116          | 103            | 89             | 87  | 97                    |
| 3                         | 104        | 108          | 105            | 110            | 94  | 126                   |
| 1                         | 98         | 89           | 102            | 94             | 91  | 121                   |

## Cell lysates Experiments

To validate the assay kit, Stimulated Jurkat cells were used. The standard curve should be performed in AlphaLISA Lysis Buffer.

Jurkat cells were grown in RPMI 1640 + 10% FBS to confluence and then plated into wells of a 96 well culture plate with the following amounts:  
40 000; 20 000; 10 000; 5 000; 2 500; 1 250; 625; 313; 157; 79; 39 and 0 cells in RPMI + 10% FBS. Cells were treated as the following:


- One group was left untreated
- One group received 20 ng/mL of phorbol myristate acetate (PMA)
- One group received 2 ug/mL of phycohemagglutinin (PHA)
- One group received both.

The cells were left overnight.

The plate was centrifuged for 5 minutes at 1500 g, and the supernatant was carefully taken out and deposited in wells of a 96 well polypropylene plate. Each well received an equivalent volume of AlphaLISA Lysis buffer 1X.


To the cell pellet was added 100 uL of AlphaLISA Lysis buffer 1X and the plate was incubated for 30 minutes at 37°C.

The lysate was tested against a standard curve of analyte in Lysis Buffer.




Signal can be observed starting at 2 500 cells per well. The signal is maximal where cells are treated with both PMA and PHA, as reported by Ryan, Lopez, Milton and Bardy (1991) Blood 77(6) pp 1195-1202.

Extrapolation on the standard curve show that the expression of IL-3 is linear to the number of cells present.




## Cell supernatant Experiments

The cell supernatants collected above were also tested using a standard curve of human IL-3 diluted in RPMI 1640 + 10% FBS: AlphaLISA Lysis buffer 1:1.




Cells also show maximum expression when treated with both PMA and PHA. Extrapolations of the results for treated cells on the standard curve also show linear expression.



## Human Serum and Plasma Experiments

Human serum and plasma from health donors were diluted 1:1 with AlphaLISA lysis buffer. Dilutions of 1:1, 1:2, 1:4, 1:8, 1:16 1:32 were performed with FBS:AlphaLISA Lysis buffer 1:1. A standard curve was also created using the protocol described above using FBS:AlphaLISA Lysis buffer 1:1 as the diluent.

Results obtained for the serum and plasma dilutions were plotted on the standard curve.



All results were multiplied by two to account for the dilution in AlphaLISA Lysis buffer. Also, to note is that raw serum or plasma gave very high background, non-linear with the other dilutions. As such, a 1:1 dilution of serum or plasma samples is recommended.

## Specificity Experiments

Cross-reactivity of the human IL-3 kit was tested using the following proteins up to 1 µg/mL in IAB.

| Protein                      | % Cross-reactivity |
|------------------------------|--------------------|
| Recombinant IL-3 from E.coli | 104                |
| Mouse IL-3                   | 0.3                |

## Troubleshooting Guide

You will find detailed recommendations for common situations you might encounter with your AlphaLISA Assay kit at:

[http://www.perkinelmer.com/in/resources/technicalresources/applicationsupportknowledgebase/alphalisa-alphascreen-no-washassays/alpha\\_troubleshoot.xhtml](http://www.perkinelmer.com/in/resources/technicalresources/applicationsupportknowledgebase/alphalisa-alphascreen-no-washassays/alpha_troubleshoot.xhtml)

**FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.**

**This product is not for resale or distribution except by authorized distributors.**

**LIMITED WARRANTY:** PerkinElmer warrants that, at the time of shipment, the above named product is free from defects in material and workmanship and conforms to the specifications set forth above. PerkinElmer makes no other warranty, express or implied with respect to the product and expressly disclaims any warranty of merchantability or fitness for any particular purpose. Notification of any breach of the foregoing warranty must be made within 60 days of receipt of the product, unless otherwise provided in writing by PerkinElmer. No claim shall be honored if the customer fails to notify PerkinElmer within the period specified. The sole and exclusive remedy of the customer for any breach of the foregoing warranty is limited to either the replacement of the non-conforming product or the refund of the invoice price of the product. PERKINELMER SHALL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, WHETHER BASED ON CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF THE DESIGN, MANUFACTURE, SALE, DELIVERY, OR USE OF THE PRODUCTS, EVEN IF THE LIMITED REMEDIES PROVIDED HEREIN FAIL OF THEIR ESSENTIAL PURPOSE OR PERKINELMER IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

PerkinElmer, Inc.  
940 Winter Street  
Waltham, MA 02451 USA  
P: (800) 762-4000 or  
(+1) 203-925-4602  
[www.perkinelmer.com](http://www.perkinelmer.com)



---

For a complete listing of our global offices, visit [www.perkinelmer.com/ContactUs](http://www.perkinelmer.com/ContactUs)

Copyright © 2012, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners.